Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria

Hypertension Research

Volumn 35, Issue 8, 2012, Pages 874-881

  Abe, Masanori ^a   Maruyama, Noriaki ^a   Suzuki, Hiroko ^a   Fujii, Yuki ^a   Ito, Midori ^a   Yoshida, Yoshinori ^a   Okada, Kazuyoshi ^a   Soma, Masayoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

aldosterone; aliskiren; chronic kidney disease; diabetic nephropathy; oxidant stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; ALDOSTERONE; ALISKIREN; AMLODIPINE; CREATININE; FATTY ACID BINDING PROTEIN; POTASSIUM; TELMISARTAN;

ADULT; AGED; ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC HYPERTENSION; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG ERUPTION; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOTENSION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ALBUMINURIA; ALDOSTERONE; AMIDES; AMLODIPINE; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DEOXYGUANOSINE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACID-BINDING PROTEINS; FEMALE; FUMARATES; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; RENIN; YOUNG ADULT;

EID: 84864688571     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2012.45     Document Type: Article

References (40)

1. Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertension Res 2009; 32: 4-107.
2. Wong ND, Lopez VA, L'Italien GL, Chen R, Kline S, Franklin S. Inadequate control of hypertension in US adults with cardiovascular disease co morbidities in 2003-2004. Arch Int Med 2007; 167: 2431-2436.
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Eng J Med 1993; 329: 1456-1462.
4. Brenner BM, Cooper MD, De Zeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 2001; 345: 861-869.
5. Lavermann GD, Henning RH, De Jong PE, Navis G, De Zeeuw D. Optimal antiprotei-nuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 2001; 38: 1381-1384.
6. Waeber B. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. J Hypertens 2006; 24: 19-27.
7. Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M et al. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143-151.
8. Ferrario C. Role of angiotensin II in cardiovascular disease-therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst 2006; 7: 3-14.
9. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Itoh H. The (pro)renin receptor and the kidney. Semin Nephrol 2007; 27: 524-528.
10. Balakumar P, Jagadeesh G. Cardiovascular and renal pathologic implications of prorenin, renin, and the (pro)renin receptor: promising young players from the old renin-Angiotensin-Aldosterone system. J Cardiovasc Pharmacol 2010; 56: 570-579.
11. Riccioni G. Aliskiren in the treatment of hypertension and organ damage. Cardiovasc Ther 2011; 29: 77-87.
12. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006; 24: 243-256.
13. Ito S, Nakura N, Breton SL, Keefe D. Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertens Res 2010; 33: 62-66.
14. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006; 29: 997-1005.
15. Persson F, Lewis JB, Rossing P, Hollenberg NK, Parving HH. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol 2011; 6: 1025-1031.
16. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NKAVOID Study Investigators. Aliskiren combined with losartan in type-2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446.
17. Nakamura T, Sato E, Amaha M, Kawagoe Y, Maeda S, Yamagishi S. Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria. J Renin Angiotensin Aldosterone Syst 2012; 13: 122-127.
18. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
19. Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C et al. Renal effects of aliskiren compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria. Diabetes Care 2009; 32: 1873-1879.
20. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD et al. Time course of the antiproteinuric and abtihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008; 73: 1419-1425.
21. Thomas MC, Burns WC, Cooper ME. Tubular changes in early diabetic nephropathy. Adv Chronic Kid Dis 2005; 12: 177-186.
22. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 818-820.
23. Goodarzi MT, Navidi AA, Rezaei M, Rezaei HB. Oxidative damage to DNA and lipids: Correlation with protein glycation in patients with type 1 diabetes. J Clin Lab Anal 2010; 24: 71-76.
24. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288: 2579-2588.
25. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 2005; 28: 2728-2732.
26. Abe M, Matuyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb 2011; 18: 1018-1028.
27. Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N et al. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004; 143: 23-30.
28. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med 2005; 145: 125-133.
29. Kasai H. Analysis of a form of oxidative DNA damage 8-hydroxy-2- deoxyguanosine as a marker of cellular oxidative stress during carcinogenesis. Mutat Res 1997; 387: 146-163.
30. Hata I, Kaji M, Hirano S, Shigematsu Y, Tsukahara H, Mayumi M. Urinary oxidative stress markers in young patients with type 1 diabetes. Pediatr Int 2006; 48: 58-61.
31. Kanauchi M, Nishioka H, Hashimoto T. Oxidative DNA damage and tubulointerstitial injury in diabetic nephropathy. Nephron 2002; 91: 327-329.
32. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002; 161: 1773-1781.
33. Struthers AD, MacDonald TM. Review of aldosterone-And angiotensin II induced target organ damage and prevention. Cardiovasc Res 2004; 61: 663-670.
34. Yoshida K, Kim-Mitsuyama S, Wake R, Izumi Y, Yukimura T, Ueda M et al. Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens Res 2005; 28: 447-455.
35. Shiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006; 47: 312-318.
36. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005; 16: 2906-2912.
37. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH et al. AVOID Study Investigators. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care 2010; 33: 2304-2309.
38. Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D et al. The effect of combination treatment with aliskiren and blockers of the renin-Angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-Analysis. BMJ 2012; 344: e42.
39. http://www.novartis.com/newsroom/media-releases/en/2011/1572562.shtml.
40. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24: 1663-1671.